The global Huntington’s Disease Treatment Market size is expected to reach USD 1.8 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 19.6% from 2022 to 2030. This growth is due to high R&D investments for new product development, research collaboration, and the high HD burden in western countries. Huntington's disease is a rare inherited neurodegenerative disease that affects several generations. It affects people between the ages of 30 and 50, impairing their capacity to work, care for their families, and, eventually, complete daily tasks.
The prevalence varies by more than ten-fold between
geographical locations, which can be related to variations in case
ascertainment and diagnostic criteria. The prevalence varies by more than
ten-fold between geographical locations, which can be related to variations in
case ascertainment and diagnostic criteria. As a result, the prevalence of
enlarged repetitions in the general population may be greater than expected.
The Asian population has consistently had a lower prevalence, while Europe,
North America, and Australia have a higher prevalence.
The key players, such as Neurocrine Biosciences, Inc.
and Azevan Pharmaceuticals, Inc., are focusing on research and development of
symptomatic therapies for HD. Azevan Pharmaceuticals is developing SRX246 as an
experimental drug to treat neuropsychiatric symptoms in Huntington's disease.
SRX246 is a drug that works by blocking the vasopressin 1a (V1a) receptor in
the brain. In the neurological system, V1a receptor is the major vasopressin
receptor. SRX246 works by inhibiting the V1a receptor, restricting vasopressin
from attaching to the receptor, and generating irritable and aggressive
behavior, which is seen in Huntington's disease patients.
However, currently approved drugs provide symptomatic
and palliative care and do not target the underlying cause of the disease.
While medications can decrease the severity of symptoms, they are often
associated with adverse effects such as somnolence, gait issues, dysphagia, and
apathy, which can have serious impacts on a patient’s quality of life. Given
the lack of a cure for the disease, it is critical to evaluate how
Health-related Quality of Life (HRQOL) is affected in these patients. HD
patients in early to middle stages of the disease need coordinated
multidisciplinary healthcare services, including assessment of cognitive
function and counseling.
Drug development for HD has faced significant
obstacles as several therapies have failed to demonstrate efficacy or were
associated with significant toxicity. Vaccinex Inc.'s phase II trial of
Pepinemab failed to satisfy pre-specified co-primary endpoints in patients with
early manifest and prodromal HD, in September 2020. The two co-primary
endpoints—a family of two cognitive evaluations from the Huntington's disease
Cognitive Assessment Battery and Clinical Global Impression of Change
(CGIC)—did not attain statistical significance in the early manifestation
population in the SIGNAL study.
Related Press Release@ Huntington’s Disease Treatment Market Report
Huntington’s Disease Treatment
Market Report Highlights
- The symptomatic treatment segment accounted for the largest revenue
share in 2021 owing to the product availability and patent protection.
Disease-modifying therapies is anticipated to be the fastest-growing
segment over the forecast years due to the entry of SAGE-718, and
Cellavita-HD
- Companies are now focusing on the development of treatments that
can be injected directly into the brain to directly inhibit the formation
of mutant HTT protein, instead of targeting the mutant protein
- Drugs with novel targets in early-phase development include
Cellavita and Azidus Brazil’s Cellavita HD (stem cell therapy), Sangamo
Therapeutics, Inc. mHTT ZFP (zinc finger protein), and UniQure’s AMT-130
(gene therapy)
- North America held the highest revenue share in 2021 and is
expected to dominate the market over the forecast period due to better
reimbursement facilities and the high burden of HD in the U.S. and Canada
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment